Avenue Therapeutics Files 8-K on Shareholder Votes

TL;DR

AVTX filed an 8-K for shareholder votes - check for major company decisions.

AI Summary

Avenue Therapeutics, Inc. filed an 8-K on December 30, 2025, reporting on matters submitted to a vote of its security holders. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.

Why It Matters

This filing indicates important corporate actions or decisions requiring shareholder approval, which could impact the company's strategic direction and shareholder rights.

Risk Assessment

Risk Level: low — This is a routine corporate filing regarding shareholder votes and does not inherently signal significant financial or operational risk.

Key Players & Entities

• Avenue Therapeutics, Inc. (company) — Registrant
• December 30, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154 (address) — Principal Executive Offices
• 001-38114 (identifier) — Commission File Number

FAQ

Filing Documents

• tm2534543d1_8k.htm (8-K) — 33KB
• 0001104659-25-125420.txt ( ) — 189KB
• atxi-20251230.xsd (EX-101.SCH) — 3KB
• atxi-20251230_lab.xml (EX-101.LAB) — 33KB
• atxi-20251230_pre.xml (EX-101.PRE) — 22KB
• tm2534543d1_8k_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 30, 2025, Avenue Therapeutics, Inc. (the " Company " or " Avenue ") held its 2025 annual meeting of stockholders (the " Annual Meeting ") at 10:00 a.m. Eastern Time by means of an online virtual meeting platform. At the 2025 Annual Meeting, the following proposals were approved: (i) the election of six directors to hold office until the 2026 annual meeting of stockholders; and (ii) the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025. These proposals are described in detail in the definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on December 5, 2025. As of the November 25, 2025 record date for the determination of the stockholders entitled to notice of, and to vote at, the 2025 Annual Meeting, 3,183,426 shares of Common Stock were outstanding and eligible to vote with an aggregate of 3,183,426 votes and 250,000 shares of the Company's Class A Preferred Stock were outstanding and eligible to vote with an aggregate of 3,500,000 votes, as determined in accordance with Article IV, Section 2.1.2 of the Company's Third Amended and Restated Certificate of Incorporation, as amended. Proposal 1 The votes with respect to the election of six directors to hold office until the 2026 annual meeting of stockholders were as follows: Director Votes For Votes Withheld Broker Non-Votes Jay Kranzler, M.D., Ph.D. 3,861,508 106,488 0 Faith Charles 3,862,060 105,936 0 Neil Herskowitz 3,861,974 106,022 0 Alexandra MacLean, M.D. 3,861,559 106,437 0 Curtis Oltmans 3,862,009 105,987 0 Lindsay A. Rosenwald, M.D. 3,861,558 106,438 0 Proposal 2 The vote on the proposal to ratify the selection of KPMG LLP as Avenue's independent registered accounting firm for the year ending December 31, 2025 was as follows: Total Votes For Total Vot

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVENUE THERAPEUTICS, INC. (Registrant) Date: December 31, 2025 By: /S/ DAVID JIN David Jin Interim Principal Financial Officer and Chief Operating Officer

View Full Filing

View this 8-K filing on SEC EDGAR